.png "United Therapeutics (NASDAQ: UTHR)")
Oppenheimer analyst Hartaj Singh maintained a Buy rating on United Therapeutics (UTHR) yesterday and set a price target of $160. The company’s shares closed yesterday at $113.22.
Singh said:
“United Therapeutics (UTHR) picked up a quality asset on 11/15/18 in ralinepag, a next-generation, oral, selectively potent, once-daily IP receptor agonist intended for treatment of pulmonary arterial hypertension (PAH). From Arena’s (ARNA) 2018 R&D Day presentation, it’s fairly apparent that this is a quality asset, with potential to be a best-in-class IP receptor agonist and challenge Uptravi (selexipag) in this category. We believe ARNA’s clinical program for ralinepag (now assumed by UTHR, upon HSR closing) encapsulates all best-in-class metrics from the development of the last few years. We await greater visibility on ralinepag phase 3’s timing/market positioning before incorporating into our valuation. We stay bullish.”
According to TipRanks.com, Singh is a 3-star analyst with an average return of 1.9% and a 38.1% success rate. Singh covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Syndax Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
United Therapeutics has an analyst consensus of Hold, with a price target consensus of $136.17.
See today’s analyst top recommended stocks >>
Based on United Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $107 million. In comparison, last year the company had a net profit of $276 million.
Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.
Read More on UTHR:
